NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Medovex Corp. (Nasdaq:MDVX), a developer of medical products, including the DenerVex device, today announced that it has priced its initial public offering of 1,391,305 units, each unit consisting of one share of common stock and one Series A Warrant, at a price to the public of $5.75 per unit. The units are expected to begin trading on The NASDAQ Capital Market on December 19, 2014 under the ticker symbol "MDVXU." The closing of the offering is expected to occur on December 24, 2014, subject to customary closing conditions. Medovex intends to use the net proceeds it receives from the offering to fund its clinical trials and product development, related regulatory expenses, and general administrative expenses, and for general working capital purposes.
All of the Units are being offered by Medovex pursuant to a registration statement that was declared effective by the Securities and Exchange Commission on December 18, 2014. In addition, Medovex has granted the underwriters a 30-day option to purchase up to an additional 208,695 units at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.
Laidlaw & Company (UK) Ltd. is acting as sole book-running manager of the offering.
The offering is being made solely by means of a prospectus. A final prospectus for the offering may be obtained from Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor, New York, NY, 10036, telephone: 212-953-4900.